We are proud to announce that Biodextris has commissioned a dedicated 30,000 sq.ft. custom-designed cGMP biomanufacturing facility including development and analytical capabilities to cater to growing demands. The bioprocessing building includes:
- 6,000 sq.ft. segregated cGMP biomanufacturing suites
- 2,500 sq.ft. controlled material warehousing
- 8,000 sq.ft. process development and analytical / QC laboratories
Biodextris is well known for its agility and the increase in available cGMP bioproduction suites will allow us to continue to adapt to our growing customer needs. Our production capacity will be expanded by the addition of 200L bioreactors as well as aseptic filling capacity.
The new analytical/QC laboratory will benefit from the addition of new equipment to support the increasing number of techniques performed internally as well as to ensure that the latest technologies are available to Biodextris clients.
This investment in cGMP biomanufacturing infrastructure and analytical capabilities is a key element of our strategy. It supports our mission as a CDMO to bring innovation to life, by offering our partners and client a facility capable of carrying their projects from early clinical phases to commercial production. This extension of capabilities is also an integral part of the strategy of the Clean Biologics group to propose integrated CDMO services for biopharma sponsors.
The newly constructed analytical laboratories and cGMP bioprocessing facility is located in the Cité de la Biotech Laval and is set to be ready for operation during the summer of 2023.
Please reach out to the team for additional information.